Success Stories: 12 Days after Filing, EB-1A Petition Approved for Research Fellow from India in the Field of Cancer Microbiome
Client’s Testimonial:
“Thank you so much for your support through out the process.”
On March 8th, 2017, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Fellow in the Field of Cancer Microbiome (Approval Notice).
General Field: Cancer Microbiome
Position at the Time of Case Filing: Research Fellow
Country of Origin: India
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: Maryland
Approval Notice Date: March 8th, 2017
Processing Time: 13 Days (Premium Processing Requested)
Case Summary:
Thanks to Premium Processing, our client’s EB-1A (Alien of Extraordinary Ability) petition was approved in merely 12 days. With a doctoral degree and extensive experience in the field of cancer microbiome, it came as no surprise that the USCIS approved our client’s EB1A petition. In preparing our client’s case, we left no stone unturned and gathered as much information as we could on his studies and their outcomes. These are some of the key points we focused on:
- We listed the 222 times our client’s work was cited by other researchers around the world. This proved to the USCIS that he is significantly contributing to the field.
- The 16 publications to our client’s name were also highlighted, and we convinced the USCIS that this is a productive publication record.
- We also noted the dozen times our client served as a peer reviewer for a handful of scientific journals. As only the cream of the crop are invited to assess the work of others, our client’s notable review experience demonstrated his respected standing in the field.
- We urged our client to obtain recommendation letters from other experts in the field and included them in the EB1A presentation. These letters highlighted the significance our client’s work the development of co-therapies that combat the tremendous side effects of life-saving anti-cancer drugs, such as hearing loss, gut toxicity, and kidney toxicity. They also supported the approval of his EB1A petition. As an example, this is what one of our client’s recommenders noted: “As a leading researcher in his field, [Client’s] unique expertise is unmatched by his peers, and, it would be highly difficult to replace him with another equally qualified researcher. [Client] has proven himself a preeminent expert in the field, and, therefore, his continued participation in hearing loss and cancer therapy research is in the best interests of the United States.”